Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cintas Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Cintas Corporation trades at $181.96 (market cap $72.76B). The key difference: Cintas Corporation is far larger — about 16.2× ACADIA Pharmaceuticals Inc.'s market cap, and Cintas Corporation pays a 0.99% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CTAS | |
|---|---|---|
Market Cap | $4.49B | $72.76B |
Sector | Health | Industrials |
52-Week High | $28.06 | $226.27 |
52-Week Low | $20.06 | $163.55 |
Enterprise Value | $3.69B | $75.49B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CTAS trades at $181.83, up 0.29% with a bullish technical signal. The stock shows strong fundamentals with revenue growing from $7.9B in 2022 to $10.3B in 2025 and net income margins expanding to 17.57%. Recent earnings mostly beat expectations, and the company maintains a 43-year dividend growth streak. Positive sentiment is supported by analyst coverage and recent corporate recognitions.
Outlook remains positive with a consensus price target of $212.50, implying 17% upside. Risks include elevated valuation multiples (P/E 37.6) and integration challenges from the UniFirst acquisition. The stock offers growth and income appeal but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
